针对阿尔茨海默氏症的抗胺治疗的进展和挑战:综合性审查
Semira Abdi Beshir1, Nadia Hussain2,3, Vineetha Bharathan Menon4
1Department of Pharmacy Practice Dubai Pharmacy College for Girls, Dubai, UAE.
International journal of Alzheimer's disease
|July 31, 2024
概括
最近的阿尔茨海默病 (AD) 治疗向的是粉样β (Aβ) 蛋白质. 一种新疗法Lecanemab减缓了认知衰退,但有副作用和需要进一步研究的访问挑战.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是粉样蛋白-β (Aβ) 和神经纤维状结积累.
- 抗粉胺疗法代表了AD治疗策略的重大进步.
研究的目的:
- 审查阿尔茨海默病抗粉样蛋白治疗的最新进展和挑战.
- 总结来自抗粉胺治疗试验的证据,重点关注lecanemab.
主要方法:
- 对抗胺类药物治疗近期进展的叙述性综述.
- 来自临床试验的证据摘要,包括Clarity AD对lecanemab的试验.
主要成果:
- 针对Aβ原纤维细胞的单克隆抗体Lecanemab证明了早期AD和轻度认知障碍 (MCI) 的认知衰退的减缓.
- 克拉里蒂AD试验报告了lecanemab的输液部位反应 (26.4%) 和粉样蛋白相关的成像异常 (12.6%).
- 莱卡尼马布的批准激发了对其他抗粉胺剂 (如多纳尼马布) 的兴趣.
结论:
- 莱卡涅马布在治疗早期阿尔茨海默病方面表现有前途,但需要进一步纵向观察临床相关性和长期副作用.
- 对于常规临床使用,必须解决包括管理,测试要求,成本,可访问性和潜在副作用在内的重大挑战.
- 未来的研究应该优先考虑AD预防,验证的血生物标志物,以及开发多目标,用户友好,成本有效的疗法.
相关概念视频
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Drug Therapy
41
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
41
Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241
Dementia
109
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
109


